

AHCL/ SE/ 54 /2021-22

February 11 2022

<b>The National Stock Exchange of India Limited</b> "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	<b>BSE Limited</b> Department of Corporate Services 1 <sup>st</sup> Floor, P.J. Towers, Dalal Street, Mumbai 400 001
<b>Symbol : AMRUTANJAN</b>	<b>Scrip Code: 590006</b>

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting**

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (**February 11, 2022**) had inter-alia:

- (i) Approved the Un-audited Financial Results for the quarter ended December 31, 2021. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared Second Interim Dividend of Re.1/- per share for the financial year 2021-22 on the Equity Shares of the Company.

The Board Meeting commenced at 10.00 A.M. and concluded at **14:30 P.M.** Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited

**(M Srinivasan)**  
**Company Secretary & Compliance Officer**



**Encl:**

1. Un-audited Standalone Financials Results for the quarter ended December 31 2021
2. Limited Review Report

**Amrutanjan Health Care Limited**

103, (Old No. 42-45), Luz Church Road,  
Mylapore, Chennai - 600 004  
Tamil Nadu, India.  
Tel :+91-44 - 2499 4465  
+91-44 - 2466 9000  
Fax :+91-44 - 2499 4585

E-mail : [customercare@amrutanjan.com](mailto:customercare@amrutanjan.com)  
Web Site : [www.amrutanjan.com](http://www.amrutanjan.com)  
Toll Free No. : 1 - 800 - 425 - 4545  
CIN - L24231TN1936PLC000017

**AMRUTANJAN HEALTH CARE LIMITED**  
CIN No : L24231TN1936PLC000017  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Statement of Unaudited Financial Results for the quarter and nine months ended 31 December 2021**

(Rs. in Lakhs)

Particulars	Quarter ended			Period ended		Year ended
	31 December 2021 (Unaudited)	30 September 2021 (Unaudited)	31 December 2020 (Unaudited)	31 December 2021 (Unaudited)	31 December 2020 (Unaudited)	31 March 2021 (Audited)
<b>Income</b>						
I Revenue from operations	11,069.59	11,038.20	10,009.70	29,928.94	23,862.72	33,284.40
II Other income	319.83	428.51	254.48	1,022.23	863.91	1,132.01
III <b>Total income (I + II)</b>	<b>11,389.42</b>	<b>11,466.71</b>	<b>10,264.18</b>	<b>30,951.17</b>	<b>24,746.63</b>	<b>34,416.41</b>
<b>Expenses</b>						
(a) Cost of materials consumed	3,004.76	3,071.67	3,139.31	8,739.89	6,427.05	8,705.95
(b) Purchases of stock-in-trade	1,717.37	1,838.34	988.68	4,636.72	2,827.61	4,812.00
(c) Changes in inventories of finished goods, work in progress and stock in trade	(41.68)	70.89	(116.01)	(334.96)	713.54	500.57
(d) Employee benefits expense	1,159.67	1,207.77	1,055.31	3,592.50	2,951.20	4,170.33
(e) Advertisement and selling expenditure	1,972.35	1,742.46	1,554.12	4,646.95	2,739.47	4,598.94
(f) Finance cost	2.98	6.91	4.29	18.37	13.29	50.00
(g) Depreciation and amortisation expense	87.72	80.46	84.41	260.22	267.97	366.97
(h) Other expenses	694.75	812.60	739.76	2,335.75	1,987.20	3,021.20
<b>Total expenses</b>	<b>8,597.92</b>	<b>8,831.10</b>	<b>7,449.87</b>	<b>23,896.44</b>	<b>17,927.33</b>	<b>26,226.96</b>
V <b>Profit before tax (III - IV)</b>	<b>2,791.50</b>	<b>2,635.61</b>	<b>2,814.31</b>	<b>7,055.73</b>	<b>6,819.30</b>	<b>8,190.45</b>
VI Tax expenses	733.72	650.83	715.75	1,807.43	1,723.14	2,071.41
VII <b>Profit for the period (V - VI)</b>	<b>2,057.78</b>	<b>1,984.78</b>	<b>2,098.56</b>	<b>5,248.30</b>	<b>5,096.16</b>	<b>6,119.04</b>
VIII <b>Other comprehensive income</b>						
Re-measurement (losses) / gains on defined benefit plans, net of taxes	(24.24)	(39.73)	(21.23)	(66.56)	(7.48)	(2.80)
<b>Total other comprehensive income/ (loss) for the period</b>	<b>(24.24)</b>	<b>(39.73)</b>	<b>(21.23)</b>	<b>(66.56)</b>	<b>(7.48)</b>	<b>(2.80)</b>
IX <b>Total comprehensive income for the period (VII + VIII)</b>	<b>2,033.54</b>	<b>1,945.05</b>	<b>2,077.33</b>	<b>5,181.74</b>	<b>5,088.68</b>	<b>6,116.24</b>
Paid-up equity share capital (Face value Re. 1/- each)	292.31	292.31	292.31	292.31	292.31	292.31
Basic earnings per share	7.05	6.79	7.18	17.97	17.43	20.94
Diluted earnings per share	7.03	6.77	7.18	17.92	17.43	20.93
	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
<i>See accompanying notes to financial results</i>						

Date: 11 February 2022  
Place: Chennai

*[Handwritten Signature]*



**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
**Registered Office: No. 103 (Old No. 42-45), Luz Church Road**  
**Mylapore, Chennai - 600 004**

**Notes:**

1. The above financial results for the quarter and nine months ended 31 December 2021 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 11 February 2022. The above results have been subjected to limited review by the statutory auditor of the Company. The auditors have issued an unmodified review report.


2. The financial results has been prepared in accordance with recognition and measurement principles laid down in accordance with the Indian Accounting Standard ('Ind AS'), 34 - "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015.

3. Interim Dividend of Re. 1/- per share, aggregating to INR 292.31 Lakhs has been paid during the quarter ended 31 December 2021

4. **Segment reporting in the financial results:** Based on the 'Management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

A	Particulars	Quarter ended			Period ended		Year ended
		31 December 2021 (Unaudited)	30 September 2021 (Unaudited)	31 December 2020 (Unaudited)	31 December 2021 (Unaudited)	31 December 2020 (Unaudited)	31 March 2021 (Audited)
<b>1</b>	<b>Segment revenue</b>						
a	OTC Products	10,648.32	10,445.67	9,721.88	27,814.14	22,929.34	31,426.35
b	Beverages	379.74	547.10	232.69	2,001.08	858.86	1,708.32
c	Others	41.53	45.43	55.13	113.72	94.52	149.73
	<b>Total</b>	<b>11,069.59</b>	<b>11,038.20</b>	<b>10,009.70</b>	<b>29,928.94</b>	<b>23,882.72</b>	<b>33,284.40</b>
<b>2</b>	<b>Segment results</b>						
a	OTC Products	2,581.91	2,360.56	2,663.42	6,280.82	6,495.44	7,868.78
b	Beverages	(35.05)	35.52	(60.04)	86.10	(285.81)	(350.16)
c	Others	(22.29)	(25.65)	(21.42)	(82.72)	(84.34)	(103.71)
	<b>Total</b>	<b>2,524.57</b>	<b>2,370.43</b>	<b>2,581.96</b>	<b>6,284.20</b>	<b>6,125.29</b>	<b>7,414.91</b>
	<b>Less :</b>						
i)	Finance cost	2.98	6.91	4.29	18.37	13.29	50.00
ii)	Other unallocable expenditure net of (unallocable income)	(269.91)	(272.09)	(236.64)	(789.90)	(707.30)	(625.54)
	<b>Total profit before tax</b>	<b>2,791.50</b>	<b>2,635.61</b>	<b>2,814.31</b>	<b>7,055.73</b>	<b>6,819.30</b>	<b>8,190.45</b>
<b>3</b>	<b>Segment assets</b>						
a	OTC Products	6,998.04	6,484.66	4,922.66	6,998.04	4,922.66	5,103.74
b	Beverages	1,876.82	1,343.56	881.21	1,876.82	881.21	910.23
c	Others	73.55	77.33	105.82	73.55	105.82	97.84
d	Unallocated assets	23,167.59	23,184.54	21,201.34	23,167.59	21,201.34	21,315.26
	<b>Total</b>	<b>32,116.00</b>	<b>31,089.09</b>	<b>27,111.03</b>	<b>32,116.00</b>	<b>27,111.03</b>	<b>27,427.07</b>
<b>4</b>	<b>Segment liabilities</b>						
a	OTC Products	5,310.12	5,145.96	4,788.40	5,310.12	4,788.40	4,362.76
b	Beverages	463.96	599.88	452.73	463.96	452.73	871.05
c	Others	70.84	79.98	105.26	70.84	105.26	94.73
d	Unallocated liabilities	711.75	1,363.76	946.67	711.75	946.67	542.06
	<b>Total</b>	<b>6,556.67</b>	<b>7,189.58</b>	<b>6,293.06</b>	<b>6,556.67</b>	<b>6,293.06</b>	<b>5,870.60</b>
	<b>Total capital employed in the Company</b>	<b>25,559.33</b>	<b>23,900.51</b>	<b>20,817.97</b>	<b>25,559.33</b>	<b>20,817.97</b>	<b>21,556.47</b>

For Amrutanjan Health Care Limited



S Sambhu Prasad  
Chairman & Managing Director

Date: 11 February 2022  
Place: Chennai

# B S R & Co. LLP

Chartered Accountants

KRM Tower, 1<sup>st</sup> & 2<sup>nd</sup> Floors,  
No.1, Harrington Road, Chetpet,  
Chennai – 600 031, India

Telephone: +91 44 4608 3100  
Fax: +91 44 4608 3199

**Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 31 December 2021 and year-to-date results for the period from 1 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

## To the Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of Amrutanjan Health Care Limited ("the Company") for the quarter ended 31 December 2021 and year-to-date results for the period from 1 April 2021 to 31 December 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP  
Chartered Accountants  
Firm's Registration No.:101248W/W-100022



K Raghuram  
Partner

Membership No.: 211171  
UDIN:22211171ABIUQS6900

Chennai  
11 February 2022